Detalhe da pesquisa
1.
α-FAtE: A new predictive score of response to atezolizumab plus bevacizumab for unresectable hepatocellular carcinoma.
Int J Cancer
; 154(6): 1043-1056, 2024 Mar 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-37994647
2.
Simple Scoring System for Esophagogastric Varices Prediction in Hepatocellular Carcinoma Patients without Liver Stiffness Evaluation.
Oncology
; 102(4): 291-298, 2024.
Artigo
em Inglês
| MEDLINE | ID: mdl-37820607
3.
Comparison of prognostic impact of atezolizumab plus bevacizumab versus lenvatinib in patients with intermediate-stage hepatocellular carcinoma.
Liver Int
; 44(1): 113-124, 2024 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-37789669
4.
Diagnostic accuracy of non-invasive tests to screen for at-risk MASH-An individual participant data meta-analysis.
Liver Int
; 2024 Apr 04.
Artigo
em Inglês
| MEDLINE | ID: mdl-38573034
5.
Impact of body mass index on the prognosis of unresectable HCC patients receiving first-line Lenvatinib or atezolizumab plus bevacizumab.
Liver Int
; 44(5): 1108-1125, 2024 May.
Artigo
em Inglês
| MEDLINE | ID: mdl-38517286
6.
Combined effect of histological findings and diabetes mellitus on liver-related events in patients with metabolic dysfunction-associated steatotic liver disease.
Hepatol Res
; 2024 Apr 24.
Artigo
em Inglês
| MEDLINE | ID: mdl-38656764
7.
Diagnostic performance of shear wave measurement in the detection of hepatic fibrosis: A multicenter prospective study.
Hepatol Res
; 2024 Feb 13.
Artigo
em Inglês
| MEDLINE | ID: mdl-38349813
8.
Comparative analysis of the therapeutic outcomes of atezolizumab plus bevacizumab and lenvatinib for hepatocellular carcinoma patients aged 80 years and older: Multicenter study.
Hepatol Res
; 54(4): 382-391, 2024 Apr.
Artigo
em Inglês
| MEDLINE | ID: mdl-37983642
9.
Changes in characteristics of gastroenterology center inpatients in Japan because of rapidly aging society.
J Gastroenterol Hepatol
; 2024 Apr 18.
Artigo
em Inglês
| MEDLINE | ID: mdl-38634347
10.
Usefulness of aMAP Risk Score for Predicting Recurrence after Curative Treatment for Hepatocellular Carcinoma within Milan Criteria.
Oncology
; 101(9): 575-583, 2023.
Artigo
em Inglês
| MEDLINE | ID: mdl-37459848
11.
Nutritional Status Is Associated with Prognosis in Patients with Advanced Unresectable Hepatocellular Carcinoma Treated with Atezolizumab plus Bevacizumab.
Oncology
; 101(4): 270-282, 2023.
Artigo
em Inglês
| MEDLINE | ID: mdl-36455517
12.
Lenvatinib as Second-Line Treatment after Atezolizumab plus Bevacizumab for Unresectable Hepatocellular Carcinoma: Clinical Results Show Importance of Hepatic Reserve Function.
Oncology
; 101(10): 624-633, 2023.
Artigo
em Inglês
| MEDLINE | ID: mdl-37307798
13.
Comparison between Atezolizumab Plus Bevacizumab and Lenvatinib for Hepatocellular Carcinoma in Patients with Child-Pugh Class B in Real-World Clinical Settings.
Oncology
; 101(9): 542-552, 2023.
Artigo
em Inglês
| MEDLINE | ID: mdl-37552968
14.
Role of the Prognostic Nutritional Index in Predicting Survival in Advanced Hepatocellular Carcinoma Treated with Atezolizumab Plus Bevacizumab.
Oncology
; 101(5): 283-291, 2023.
Artigo
em Inglês
| MEDLINE | ID: mdl-36657420
15.
Spleen stiffness in patients with chronic liver disease evaluated by 2-D shear wave elastography with ultrasound multiparametric imaging.
Hepatol Res
; 53(2): 93-103, 2023 Feb.
Artigo
em Inglês
| MEDLINE | ID: mdl-36149642
16.
Clinical role of radiofrequency ablation for early-stage hepatocellular carcinoma in an advanced aging society.
Hepatol Res
; 53(7): 641-648, 2023 Jul.
Artigo
em Inglês
| MEDLINE | ID: mdl-36883289
17.
Association of abnormal glucose tolerance with liver-related disease and cardiovascular diseases in patients with chronic hepatitis C.
Hepatol Res
; 53(9): 806-814, 2023 Sep.
Artigo
em Inglês
| MEDLINE | ID: mdl-37183992
18.
Association of proton pump inhibitor and antibiotic use with the clinical outcomes of hepatocellular carcinoma patients receiving atezolizumab and bevacizumab: A multicenter analysis.
Hepatol Res
; 53(8): 737-748, 2023 Aug.
Artigo
em Inglês
| MEDLINE | ID: mdl-37020416
19.
Geriatric nutritional risk index as an easy-to-use assessment tool for nutritional status in hepatocellular carcinoma treated with atezolizumab plus bevacizumab.
Hepatol Res
; 53(10): 1031-1042, 2023 Oct.
Artigo
em Inglês
| MEDLINE | ID: mdl-37306040
20.
Impact of first-line systemic therapy with atezolizumab plus bevacizumab in patients with hepatocellular carcinoma.
J Gastroenterol Hepatol
; 38(8): 1389-1397, 2023 Aug.
Artigo
em Inglês
| MEDLINE | ID: mdl-37231943